Статья: Многоликий эглонил
29. Ruter E, Degner D, Munzel U. Antidepressant action of sulpiride. Results of a placebo–controlled double–blind trial. Pharmacopsychiatry,1999, 32,127–135
30. Meyers C, Vranckx C, Elgen K. Psychosomatic disorders in general practice: comparisons of treatment with flupentixol, diazepam and sulpiride. Pharmacotherapeutica,1985, 4, 244–250
31. Altamura AC, Mauri MC, Regazzetti G. L–sulpiride in the treatment of somatoform disturbances: a double–blind study with racemic sulpiride. Minerva Psichiatr.,2000, 32, 25–29
32. Cavazzutti E, Bertlini A, Vergoni AV et al. L–Sulpiride at a low, non–neuroleptic dose, prevents conditioned fear stress–induced fresing behavior in rats. Psychopharmacology (Berl),1999, 3, 143, 20–23
33. Ferreri M, Florent C, Gerard D, Sulpiride: study of 669 patient presenting with pain psychological origin. Encephale, 2000, 26, 58–66
34. Drago F, Arezzi A, Virzi A. Effects of acute or chronic administration of substituted benzamides in experimental models of depression in rats. Eur. Neuropsychopharmacology, 2000, 10, 437–442
35. WHO Guide to Mental Health in Primary Care. London: Royal Society of Medicine Press, 2000
36. Schultz W. Dopamine neurons and their role in reward mechanisms. Current Opinion in Neurobiology, 1997, 7, 191–197
37. Spanagel R., Weiss F. The dopamine hypothesis of reward: past and current status. Trnds in Neurosciences,1999, 22, 521–527
38. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning or ince salience? Brain Res.Rev,1998, 28, 3, 309–369
39. Vergoni AV, Forgione A, Bertolini A. Chronic administration of I–sulpiride at non–neuroleptic doses reduces the duration of immobility in experimental models of «depression–like» behavior. Psychopharmacology (Berl),1995, 121, 279–281
40. Mizuki Y. Suetsugi M, Ushijima I et al. Differential effects of dopaminergic drugs on anxiety and arousal in healthy volunteers with high and low anxiety. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1997, 21, 573–590
41. Guslandi M. Antiemetic properties of levo–sulpiride. Minerva Med.,1990, 12, 81, 855–860
42. Caldara R, Masci E, Cambielli M et al. Effect of sulpiride isomers on gastric acid and gastrin secretion in healthy man. Eur.J.Clin.Pharmacol.,1983, 25, 319–322
43. Cohen N, Alon I, Almoznino–Sarfian D et al. Sulpiride versus metoclopramide in nononcologic patiets with vomiting and nausea. J.Clin. Gastroenterol.1999, 7, 29, 59–62
44. Corazza GR, Biagi F, Albano O et al. Levosulpiride in functional dyspepsia: a multicentric, double–blind, controlled trial. Ital. J. Gastroenterol.,2000, 28, 317–323
45. Mansi C, Savarino V, Vigneri S et al. Gastrocinetic effects of levosulpiride in dyspeptic patients with diabetic gastroparesis. Am.J. Gastroenterol., 1995, 11, 90, 1989–1993
46. Mansi C, Savarino V, Vigneri S et al. Effect of D2–dopamine raceptor antagonist levosulpiride on diabetic cholecystoparesis: a double–blind crossover study. Aliment. Pharmacol. Ther.,1995, 4, 9, 185–189
47. Szabelska K, Chojnacki J, Grzegorczyk J et al. Effect of procinetic drugs inhibiting dopaminergic system on gallbladder motility in subjects with duodenal ulcer. Pol. Merkuriusz. Lek., 1999, 6, 188–191
48. Pich EM, Samanin R., Disinhibitory effects of buspirone and low doses of sulpiride and haloperidol in two experimental anxiety models in rats: possible role of dopamine. Psychopharmacology (Berl), 1986, 89, 125–130